Table 3.

Analysis of the impact of potential confounders of the autoimmune disease-30-day mortality association

Adjusting for confounders of the association between autoimmune disease and 30-day mortality	OR (95% CI)	P value	Magnitude of confounding
No confounders adjusted (“crude”)	0.71 (0.58–0.86)	< 0.001	–
Age adjusted	0.74 (0.60–0.90)	0.003	− 4.46%
Sex adjusted	0.71 (0.60–0.86)	< 0.001	− 0.31%
Race adjusted	0.71 (0.58–0.87)	< 0.001	− 0.93%
Documented bacteremia adjusted	0.68 (0.56–0.83)	< 0.001	4.41%
Infection site adjusted	0.72 (0.56–0.83)	0.001	− 1.39%
SOFA score adjusted	0.81 (0.65–1.00)	0.051	− 12.34%
Elixhauser comorbidity index adjusted	0.71 (0.57–0.86)	< 0.001	0.26%
DMARD or prednisone usage adjusted	0.66 (0.54–0.81)	< 0.001	7.58%
ICU care unit adjusted	0.71 (0.58–0.86)	< 0.001	0.10%

Magnitude of confounding = (OR_crude − OR_adjusted)/OR_adjusted

OR odds ratio, CI confidence interval, SOFA Sequential Organ Failure Assessment, DMARD disease-modifying antirheumatic drug, ICU intensive care unit